- Home
- RGCO vs AVIR Comparison
RGCO vs AVIR Comparison
Compare RGCO & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGCO
- AVIR
- Stock Information
- Founded
- RGCO 1912
- AVIR 2012
- Country
- RGCO United States
- AVIR United States
- Employees
- RGCO N/A
- AVIR N/A
- Industry
- RGCO Oil & Gas Production
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- RGCO Utilities
- AVIR Health Care
- Exchange
- RGCO Nasdaq
- AVIR Nasdaq
- Market Cap
- RGCO 236.5M
- AVIR 273.0M
- IPO Year
- RGCO N/A
- AVIR 2020
- Fundamental
- Price
- RGCO $19.68
- AVIR $3.47
- Analyst Decision
- RGCO
- AVIR Hold
- Analyst Count
- RGCO 0
- AVIR 1
- Target Price
- RGCO N/A
- AVIR $6.00
- AVG Volume (30 Days)
- RGCO 19.4K
- AVIR 392.1K
- Earning Date
- RGCO 08-12-2025
- AVIR 08-07-2025
- Dividend Yield
- RGCO 4.22%
- AVIR N/A
- EPS Growth
- RGCO N/A
- AVIR N/A
- EPS
- RGCO 1.29
- AVIR N/A
- Revenue
- RGCO $91,314,087.00
- AVIR N/A
- Revenue This Year
- RGCO $10.87
- AVIR N/A
- Revenue Next Year
- RGCO $3.26
- AVIR N/A
- P/E Ratio
- RGCO $15.22
- AVIR N/A
- Revenue Growth
- RGCO 9.74
- AVIR N/A
- 52 Week Low
- RGCO $19.05
- AVIR $2.46
- 52 Week High
- RGCO $24.20
- AVIR $4.15
- Technical
- Relative Strength Index (RSI)
- RGCO 31.98
- AVIR 46.31
- Support Level
- RGCO $20.18
- AVIR $3.36
- Resistance Level
- RGCO $23.22
- AVIR $3.97
- Average True Range (ATR)
- RGCO 0.71
- AVIR 0.19
- MACD
- RGCO -0.20
- AVIR -0.02
- Stochastic Oscillator
- RGCO 0.00
- AVIR 16.67
About RGCO RGC Resources Inc.
RGC Resources Inc is involved in the business of distribution and sale of natural gas to residential, commercial, and industrial customers within its service territory in Roanoke, Virginia, and its surrounding localities. The company also provides certain non-regulated services. The company relies on multiple interstate pipelines to transport natural gas. The company operates in three segments: Gas Utility, which is the key revenue generator; Investment in Affiliates this segment reflects the income generated through the activities of the Company's investment in MVP and Southgate projects and Parent & Other including the unregulated activities of the Company as well as certain corporate eliminations.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).